InspireMD Advances Stroke Prevention with FDA PMA Submission
Company Announcements

InspireMD Advances Stroke Prevention with FDA PMA Submission

InspireMD ( (NSPR) ) has issued an update.

InspireMD, Inc. has announced the submission of a Premarket Approval (PMA) application to the FDA for its CGuard Prime Carotid Stent System, following positive results from its C-GUARDIANS clinical trial. The trial showed a lower major adverse event rate than any previous trial of its kind, signifying a potential breakthrough in stroke prevention and carotid artery disease treatment. The company anticipates a U.S. commercial launch in the first half of 2025, pending approval.

Learn more about NSPR stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInspireMD Achieves Record Q3 Revenue with CGuard Success
TheFlyInspireMD reports Q3 EPS (16c) vs (15c) last year
Catie PowersNSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App